The report stated that Celltrion, on Tuesday, announced its U.S. subsidiary signed a contract on Saturday to acquire 100 per ...

Meanwhile, U.S. drug pricing and reimbursement was an issue for 39%, while 32% of respondents to the survey, carried out by the investment bank Lazard, cited FDA regulatory uncertainty. Compared to ...

Roche is advancing its experimental obesity drug to a late-stage trial to join top players like Eli Lilly in the weight-loss ...

The South Korean pharma company’s US subsidiary is purchasing Eli Lilly’s Branchburg, NJ site to safeguard against potential ...

Seoul: Celltrion, South Korea's leading biopharmaceutical company, said on Tuesday its US subsidiary has signed a deal to ...

South Korean biopharmaceutical company Celltrion said it would invest at least $1 billion to acquire a plant from Eli Lilly ...

After teasing its position in a bidding contest for a large-scale drug substance plant in the U.S. this summer, South Korea’s Celltrion has sealed the deal. | Celltrion—which specializes in biosimilar ...

Bristol Myers Squibb has ended its R&D losing streak with a hit on one of the dual primary endpoints in a phase 3 multiple ...

Celltrion Inc., South Korea's leading biopharmaceutical company, said Tuesday its U.S. subsidiary has signed a deal to ...

Roche advances in the obesity drug race, signaling intention to compete with Eli Lilly and Novo Nordisk. Pfizer acquires ...

Celltrion has decided to invest over 1.4 trillion won in acquiring and expanding Eli Lilly's pharmaceutical plant in New ...

SEOUL (Reuters) -- Celltrion said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems from Eli Lilly in the United States for $330 million. In a statement ...